Cantor Fitzgerald Reiterates Overweight Rating on Tenax Therapeutics, Inc. (TENX)

Market Context

Tenax Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $12.93 with a market capitalization of $45.0M.

Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tenax Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Tenax Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Cantor Fitzgerald	Overweight	N/A
Jun 22, 2026	Chardan Capital	Buy	N/A
Jun 22, 2026	Guggenheim	Buy	N/A
Jun 12, 2026	Piper Sandler	Overweight	N/A
Mar 17, 2026	Cantor Fitzgerald	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View TENX Stock Page